Bahrain approves China's Sinopharm vaccine for use

MENA

Published: 2020-12-13 16:13

Last Updated: 2024-03-28 09:32


Bahrain approves China's Sinopharm vaccine for use
Bahrain approves China's Sinopharm vaccine for use

Sunday, the National Health Regulatory Authority (NHRA) in Bahrain announced the approval of the registration of the Sinopharm coronavirus vaccine, developed by China National Pharmaceutical Group.

“Results from Phase III clinical trials showed an 86 percent efficacy rate, a 99 percent seroconversion rate of neutralizing antibody and 100 percent effectiveness in preventing moderate and severe cases of COVID-19," the NHRA said in a statement. The vaccine has been tested on 42,299 volunteers.

Bahrain participated in phase III clinical trials of the vaccine as part of the '4 Humanity campaign,' in which more than 7,700 volunteers signed up.

This is the second vaccine to be approved by the Gulf country after the Pfizer vaccine which was approved on Dec. 5. 


Also Read: Bahrain becomes second country to authorize use of Pfizer vaccine